This Week in Medicine: NHS Launches Lung Cancer Vaccine Trial & Casgevy Gene Therapy

NHS England has launched a pioneering lung cancer vaccine trial that combines artificial intelligence and robotic technology to help doctors reach hard-to-detect cancers earlier. The new approach uses AI software to rapidly analyse lung scans and flag small lumps that are most likely to be cancerous, and a robotic camera is then used to reach difficult-to-access tumours with fewer invasive tests. The pilot is designed to give patients facing suspected lung cancer answers sooner, potentially transforming the diagnostic pathway for one of the deadliest cancers.

In parallel, NHS Blood and Transplant has announced its vital role in a pioneering cancer vaccine for the most common type of lung cancer, marking another major step forward in personalised cancer immunotherapy. Meanwhile, NICE approved a once-weekly insulin injection for type 2 diabetes on 20 August 2026, which could cut the number of injections each patient needs by 85%—a significant quality-of-life improvement for hundreds of thousands of people.

Finally, gene-editing therapy Casgevy (exagamglogene autotemcel) has been approved by NICE for NHS patients over 12 with severe sickle cell disease. The CRISPR-based therapy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, represents a world-first in gene-editing treatments now available on the NHS. Clinical trials in the UK were led by researchers at Imperial College Healthcare NHS Trust.

These advances illustrate the accelerating pace of innovation in the NHS—from AI-driven diagnostics to gene therapies—offering hope for more personalised, effective, and less invasive treatments across cancer and chronic disease management.

World Physiotherapy Day falls on 8 September each year—just over a week ago from today—and serves as a global reminder of the vital role physiotherapists play in helping people recover, stay mobile, and live healthier lives. This year's theme focused on 'Physiotherapy in Healthy Ageing', highlighting the importance of physical activity and personalised care in an ageing population.

Physiotherapists work across every stage of the patient journey: from intensive care, to community rehabilitation, to first-contact musculoskeletal (MSK) services in GP practices. By 2024, all adults in England gained direct access to MSK first-contact physiotherapists at their local GP practice without needing a GP referral first—a major shift in primary care provision.

Why this matters for applicants

Physiotherapy sits at the heart of the multidisciplinary team model you'll be asked about in interviews. Understanding the scope and impact of allied health professionals (AHPs) demonstrates systems-level thinking and a genuine appreciation for collaborative care. Physiotherapists diagnose, treat, and manage patients independently; they request imaging and blood tests; and they reduce demand on overstretched GP and secondary-care services.

Key interview angles:

• Workforce pressures: Physiotherapy is one of the NHS's fastest-growing professions, yet vacancies remain high. How does expanding the physiotherapy workforce align with the NHS Long Term Plan's shift from hospital to community care?
• Health inequalities: MSK conditions disproportionately affect people in deprived areas and those with comorbidities like diabetes and depression. How can physiotherapy services be designed to reach those who need them most?
• Patient autonomy: Direct access to physiotherapy empowers patients to self-manage and make informed choices about their care. How does this reflect the broader shift towards personalised, patient-centred care in the NHS?

If you've shadowed a physiotherapist, had MSK care yourself, or worked in a setting where AHPs were integral, this is rich material for your personal statement and interview reflections. Don't reduce allied health professionals to 'support' roles—they are autonomous clinicians whose scope and impact are expanding year on year.

NICE's recent approval of Casgevy, a CRISPR-based gene-editing therapy for sickle cell disease and beta thalassaemia, brings a landmark ethical question into sharp focus: how do we decide which patients receive access to transformative but extraordinarily expensive therapies?

Casgevy is approved for NHS patients over 12 with severe forms of these blood disorders. It represents a potential cure after a single treatment, replacing lifelong transfusions and management. But gene therapies routinely cost hundreds of thousands—or even millions—of pounds per patient. In the US, similar treatments are priced at over $2 million.

The ethical tension

This is fundamentally a resource allocation dilemma, nested within the four pillars of medical ethics:

Justice demands fair distribution of scarce resources. Should a therapy be approved if it benefits a small number of patients at a cost that could fund thousands of routine treatments elsewhere? NICE uses cost-per-QALY (quality-adjusted life year) thresholds to assess value, but gene therapies often fall into a grey zone—high upfront cost, uncertain long-term data, but potentially life-changing impact.

Beneficence and non-maleficence require us to maximise benefit and minimise harm. Approving the therapy benefits those eligible patients enormously. But denying funding for other services to pay for it may harm a larger population indirectly. How do we weigh a transformative cure for one child against incremental improvements for many?

Autonomy asks: should patients have a say in this trade-off? Should clinicians be able to advocate for individual patients even when it conflicts with population-level resource constraints?

Questions for reflection

• Should the NHS use a different cost-effectiveness threshold for rare, life-limiting conditions affecting children?
• Who should decide which therapies are funded—clinicians, health economists, patients, or politicians?
• Is it ethically acceptable to approve a treatment for some patients but deny it to others based on age or disease severity, even when both groups could benefit?
• How do we balance hope and hype? Gene therapies are often described as 'miracle cures,' but they come with risks, require specialist centres, and may not work for everyone.

If asked about this in an interview, resist binary answers. Acknowledge the tension, reference the principles, and explore both sides with nuance. The NHS cannot fund everything, but deciding what not to fund is where ethics becomes unavoidable.

For deeper preparation, explore our Four Pillars of Medical Ethics guide.

With AI-driven diagnostics, gene therapies, and robotic surgery now routinely featuring in NHS announcements, you will be asked about innovation and technology in your interview. The trap? Sounding like you've just read a press release. The opportunity? Demonstrating balanced, critical thinking about how new technologies are adopted, funded, and integrated into the NHS.

Here's how to structure answers that go beyond 'AI is amazing but we need human oversight.'

1. Name the innovation, then immediately locate it in context

Don't just say 'AI is being used in radiology.' Say: 'AI is being piloted in lung cancer diagnostics to flag suspicious lesions on CT scans, helping radiologists prioritise urgent cases and reduce diagnostic delays. NHS England is rolling this out alongside robotic bronchoscopy to reach hard-to-access tumours.'

This shows you've read recent, specific developments—not generic ChatGPT summaries.

2. Use a two-sided framework

Benefits:
- Faster diagnosis and treatment
- Reduces clinician workload in overstretched specialties
- May improve outcomes in under-resourced areas (e.g., areas with radiologist shortages)

Challenges:
- High upfront cost—who pays, and what gets cut to fund it?
- Requires training, infrastructure, and maintenance (the NHS is not good at long-term IT investment)
- Risk of algorithmic bias if training data isn't representative
- Liability question: if the AI misses a cancer, who is responsible?

You don't need to solve these—just show you've thought about them.

3. Tie it back to the patient and the doctor

'Ultimately, AI is a tool to support clinical decision-making, not replace it. The doctor still needs to interpret the AI's output, communicate with the patient, and take responsibility for the decision. Technology can improve efficiency and accuracy, but it can't replace empathy, shared decision-making, or the therapeutic relationship.'

This is the 'human touch' closer that interviewers want to hear—but only after you've demonstrated technical understanding.

4. If you don't know, say so—then reason from first principles

'I haven't read about that specific technology, but I imagine the key questions would be: does it improve patient outcomes? Is it cost-effective compared to current practice? Can it be delivered equitably across the NHS, or will it widen existing inequalities? And how do we ensure clinicians are trained to use it safely?'

This shows structured thinking even when you're working without perfect information—exactly what you'll do as a junior doctor.

Bottom line: Innovation questions are not knowledge tests. They're reasoning tests. Show you can think critically, acknowledge trade-offs, and keep the patient at the centre.

For more on this topic, explore our AI in Medicine resource.

Interview season is here, and if you're feeling behind, here are three high-impact, low-time-cost actions you can take this week to sharpen your preparation.

1. Update your 'Why Medicine?' answer with a 2026 example

Your work experience from 2024 is still valid, but interviewers notice when candidates reference current NHS developments. Spend 15 minutes reading the most recent updates from NHS England or NICE. Pick one recent development—gene therapy approval, AI in diagnostics, NHS workforce plans—and weave it into your 'Why Medicine?' answer as evidence that you're keeping up with the field.

Example: 'The approval of Casgevy for sickle cell disease this August reinforced for me why I want to be part of a profession that translates cutting-edge science into real patient benefit—but also one that grapples with difficult resource allocation decisions.'

This shows ongoing engagement, not just historic interest.

2. Prepare one 'systems-level' reflection on your work experience

Most candidates can reflect on what they saw. Few can reflect on why the system worked that way. Pick one observation from your work experience and ask:

• Why was the patient waiting so long?
• Why was the physio, not the doctor, leading that clinic?
• Why did the discharge take three days?

Then research the answer. Was it a workforce issue? A funding issue? A structural problem with how primary and secondary care communicate?

This is gold-dust material for 'Tell me about a time you observed something that surprised you' or 'What challenges does the NHS face?' questions.

Our NHS Pressures and the Workforce guide will give you the language and frameworks to articulate these reflections clearly.

3. Rehearse one MMI station out loud, alone, today

Not tomorrow. Not 'when I have time.' Today. Pick any ethical scenario—consent for a minor, breaking bad news, allocating ICU beds—and speak your answer out loud for 2 minutes, timed. Record it if you can.

You'll immediately notice:
- Where you say 'um' or pause awkwardly
- Which parts of your answer are vague or repetitive
- Whether you're signposting clearly ('First, I'd consider autonomy…')

One rehearsed station, done properly, is worth ten read-throughs. Speaking out loud is the only way to simulate the cognitive load of a real interview.

For structured MMI practice and model answers, explore our Interview Preparation hub.

Bottom line: You don't need to prepare everything. You need to prepare something deeply and do it now.

The University of Edinburgh offers a distinctive six-year MBChB programme—the only Scottish medical school to embed a mandatory full-year research intercalated degree (BMedSci) in Year 3. This is not optional, and it's not an add-on: every student completes it, making Edinburgh graduates exceptionally well-prepared for academic medicine, audit, and evidence-based practice.

Programme structure

Years 1–2: Integrated teaching across biomedical sciences, clinical skills, and social/ethical aspects of medicine, with early patient contact in GP practices and hospitals across Edinburgh and southeast Scotland.

Year 3: Full-time research year leading to a BMedSci (Hons). Students design and conduct an independent research project, supervised by world-leading faculty. Many publish their findings or present at conferences—a significant CV boost for specialty training applications.

Years 4–6: Clinical attachments across a range of specialties in Edinburgh and surrounding areas, with increasing responsibility and integration into medical teams. The curriculum is designed to meet GMC Outcomes for Graduates and prepare students for Foundation Year 1.

Entry requirements (2026 entry)

Standard offer:
- A-levels: AAA (Chemistry required; plus one from Biology, Maths, or Physics)
- Scottish Highers: AAAAA by end of S5, plus BB at Advanced Higher in S6 (Chemistry and two from Biology, Maths, or Physics required at Higher level)
- GCSEs: Biology, Chemistry, English, and Maths at A/7 (or B/6 if eligible for minimum entry requirements under widening access)

Minimum offer (widening access applicants):
- A-levels: AAB (Chemistry at A; one from Biology, Maths, or Physics at A)
- GCSEs: Biology, Chemistry, English, and Maths at B/6

Graduates with a 2:1 in a relevant subject (e.g., Biomedical Sciences, Medical Sciences, Nursing) are welcomed for first-year entry, though they do not receive additional widening-access consideration unless care-experienced or refugees/asylum seekers.

UCAT

Edinburgh requires UCAT and weights it heavily. There is a minimum score threshold (updated annually—check the Edinburgh Medical School website closer to application time). Recent successful home applicants have scored in the top decile (around 2,600+ out of 3,400). Band 4 in the Situational Judgement section is an automatic rejection.

Selection process

Edinburgh does not interview most home applicants. Selection is based on:
- Academic grades (25%)
- UCAT score
- Personal statement (scored rigorously against a published rubric—Edinburgh takes this more seriously than most UK schools)

International applicants may be interviewed (typically a panel/MMI hybrid format).

What makes Edinburgh different?

• Research focus: The mandatory intercalated year produces graduates who understand how to read, critique, and conduct research—essential for career progression in any specialty.
• Academic heritage: Over 300 years of medical education; alumni include pioneers like James Young Simpson (anaesthesia) and Joseph Lister (antiseptic surgery).
• No fast-track route: Graduates cannot skip the BMedSci year, though they may bypass it in exceptional circumstances (e.g., prior research experience). Most complete the full six years.

Tuition fees (2026/27)

• Scottish students: Covered by SAAS (Student Awards Agency Scotland)
• Rest of UK (England/Wales/NI): £9,790 per year
• International students: Check university website; deposit required (one-third of annual fee)

Application tips

• Maximise your UCAT score. Edinburgh uses it as a primary filter. Aim for top decile if applying as a home student. See our UCAT Preparation hub for timed practice and strategy guides.
• Craft a personal statement that fits Edinburgh's rubric. They publish detailed guidance on how they score it—read it, then write accordingly. Generic statements are penalised.
• Emphasise research and academic curiosity. If you've done an EPQ, completed a research project, or engaged with academic literature beyond A-level, highlight it. Edinburgh values intellectual depth.
• Know the structure. Be ready to explain why you're applying to a six-year programme with a research year, not a standard five-year course.
• Check your eligibility for widening access. If you meet the criteria, you'll be considered against lower grade thresholds—but you must declare this in your UCAS application.

Edinburgh is highly competitive, intellectually rigorous, and research-intensive. It's an excellent choice for applicants who want to develop as academic clinicians, not just practitioners. If you thrive on enquiry, evidence, and academic challenge, Edinburgh's structure is designed for you.

For strategic advice on school selection and application planning, explore our Application Strategy guide. To see how Edinburgh compares across metrics like teaching quality, student satisfaction, and career outcomes, visit our Medical School Rankings.